Celebrex, NSAID Labeling Must Include Skin Reactions Warning, FDA Says
FDA is requiring labeling for non-steroidal anti-inflammatory drugs include a warning on skin reactions, in addition to a boxed warning on cardiovascular and gastrointestinal risk
More from Archive
More from Pink Sheet
Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.
Drugmakers are not expecting a big financial hit from tariffs for now, but a report commissioned by the industry trade association PhRMA suggests a potentially steep cost for pharma-sector tariffs.
EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.